Bridged androstenediol analogs as ER-beta selective SERMs.
A series of bridged androstenediol derivatives was prepared. The bridged compounds exhibited reduced ER-beta selectivity relative to uncyclized analogs.
Blizzard
Timothy A
TA
Merck Research Laboratories, PO Box 2000, Rahway, NJ 07065, USA. tim_blizzard@merck.com
Gude
Candido
C
Chan
Wanda
W
Birzin
Elizabeth T
ET
Mojena
Marina
M
Tudela
Consuelo
C
Chen
Fang
F
Knecht
Kristin
K
Su
Qin
Q
Kraker
Bryan
B
Holmes
Mark A
MA
Rohrer
Susan P
SP
Hammond
Milton L
ML
D000734:Androstenediols / Q000138:chemical synthesis* / Q000494:pharmacology; D003500:Cyclization; D047629:Estrogen Receptor beta / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000378:metabolism; D006801:Humans; D008958:Models, Molecular; D015394:Molecular Structure; D020845:Selective Estrogen Receptor Modulators / Q000138:chemical synthesis* / Q000494:pharmacology*; D013329:Structure-Activity Relationship
D000734:Androstenediols; D047629:Estrogen Receptor beta; D020845:Selective Estrogen Receptor Modulators